TB-500
Thymosin Beta-4 fragment
Synthetic fragment studied for cell migration and tissue remodeling.
Evidence Level
Emerging
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Synthetic fragment studied for cell migration and tissue remodeling.
/ 02
Mechanism of Action
Studied for actin sequestration, cell motility, and angiogenic signaling.
/ 03
Research Applications
Repair signaling, soft tissue remodeling.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
TB-500 refers to a synthetic fragment related to thymosin beta-4 biology. Research describes actin-binding behavior, modulation of cell migration, and roles in progenitor cell mobilization observed in preclinical wound and repair models.
/ 08
Pathway Role
Sits within the cell migration and tissue repair pathway, with reported influence on cytoskeletal dynamics that support repair-cell mobility.
/ 09
Biological Targets
/ 10
Research Applications
- Cardiac repair preclinical models
- Skin and corneal wound healing studies
- Skeletal muscle injury models
- Neuroprotection / neural repair preclinical research
/ 11
Evidence Summary
Evidence is largely preclinical. Mechanistic data on actin binding and cell migration is reasonably well-documented; controlled human outcome studies are limited.
Evidence Level Rationale
Rated emerging due to a strong preclinical mechanistic base but lack of robust human trial data.
/ 12
Research Observation Timeline
Early Signal Window
Cell migration changes in vitro within hours to days
Primary Study Window
Days to weeks in preclinical wound and repair models
Endpoint Type
Cellular migration and histological repair endpoints
Evidence Strength
Emerging preclinical
/ 13
Safety & Unknowns
Human safety profile is not well-characterized. Long-term immune and oncologic safety questions are not resolved in the public literature.
/ 14
Research Limitations
Findings rely heavily on animal repair models. Human outcome timing and effect size are not established.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Emerging
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
BPC-157
Pentadecapeptide studied for tissue protection and repair models.
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.